BioSight
Companies
Nurix Therapeutics, Inc. logo

NRIX

NASDAQBRISBANE, CA
Nurix Therapeutics, Inc.

Nurix Therapeutics develops drugs using protein degradation technology and antibody-drug conjugate approaches, with a platform called DEL-AI that the company uses to discover new candidates. Their lead programs in clinical development include bexobrutideg (NX-5948), zelebrudomide (NX-2127), and NX-1607, though the excerpt provided does not specify which therapeutic areas these target. Nurix has partnerships with major pharmaceutical companies including Gilead Sciences, Sanofi, and Seagen (now part of Pfizer) to help advance and commercialize its pipeline.

Price history not yet available for NRIX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar